Ultra-Low Power NIR Laser-Triggered Phototherapy and μCT Imaging of Breast Cancer In Vivo

2018 ◽  
Author(s):  
Mohamed S. Mohamed ◽  
S. Veeranarayanan ◽  
Aby C. Poulose ◽  
M. Rinya ◽  
Y. Sakamoto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Low Power ◽  
Ultra Low Power ◽  
Nir Laser

scholarly journals NIR-laser-triggered gadolinium-doped carbon dots for magnetic resonance imaging, drug delivery and combined photothermal chemotherapy for triple negative breast cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Qunjiao Jiang ◽  
Li Liu ◽  
Qiuying Li ◽  
Yi Cao ◽  
Dong Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Triple Negative Breast Cancer ◽  
Carbon Dots ◽  
Triple Negative ◽  
Resonance Imaging ◽  
Doped Carbon Dots ◽  
Nir Laser

Abstract Background Owing to high genetic diversities of tumor cells and low response rate of standard chemotherapy, patients with triple negative breast cancer (TNBC) have short progression-free survivals and poor outcomes, which need to explore an effective approach to improve therapeutic efficacy. Methods Novel gadolinium doped carbon dots (Gd@CDs) have been designed and prepared through hydrothermal method with 3,4-dihydroxyhydrocinnamic acid, 2,2′-(ethylenedioxy)bis(ethylamine) and gadolinium chloride. The synthesized nanostructures were characterized. Taking advantage of good biocompatibility of Gd@CDs, a nanoplatform based on Gd@CDs has been developed to co-deliver chemotherapy drug doxorubicin hydrochloride (Dox) and a near-infrared (NIR) photothermal agent, IR825 for magnetic resonance imaging (MRI) guided photothermal chemotherapy for TNBC. Results The as-synthesized Dox@IR825@Gd@CDs displayed favorable MRI ability in vivo. Upon NIR laser irradiation, Dox@IR825@Gd@CDs could convert the NIR light to heat and efficiently inhibit tumor growth through photothermal chemotherapy in vitro and in vivo. Additionally, the impact of photothermal chemotherapy on the murine motor coordination was assessed by rotarod test. Dox@IR825@Gd@CDs presented low toxicity and high photothermal chemotherapy efficiency. Conclusion A noble theranostic nanoplatform (Dox@IR825@Gd@CDs) was developed that could be tailored to achieve loading of Dox and IR825, intracellular delivery, favorable MRI, excellent combination therapy with photothermal therapy and chemotherapy to enhance therapeutic effect against TNBC cells. This study will provide a promising strategy for the development of Gd-based nanomaterials for MRI and combinational therapy for TNBC. Graphic abstract

A LOW-NOISE LOW-POWER FRONT-END AMPLIFIER FOR NEURAL-RECORDING APPLICATIONS

2010 ◽  
Vol 22 (04) ◽  
pp. 301-306 ◽  
Author(s):  
Mohammad Hossein Zarifi ◽  
Javad Frounchi ◽  
Mohammad A. Tinati ◽  
Shahin Farshchi ◽  
Jack W. Judy
Keyword(s):  
Low Power ◽  
Heat Dissipation ◽  
Harmonic Distortion ◽  
Low Noise ◽  
Low Noise Amplifiers ◽  
Cmos Process ◽  
Ultra Low Power ◽  
Fully Differential ◽  
Front End

Monitoring the electrical activities of a large number of neurons in vertebrates' central nervous system in vivo through hundreds of parallel channels without interferring in their natural functions is a neuroscientist's interest. Value of this information in both scientific and clinical contexts, especially in expansion of brain–computer interfaces, is extremely significant. Therefore, low-noise amplifiers are needed with filtering capability on the front end to amplify the desired signals and eliminate direct current baseline shifts. Hence, size and power consumption need to be minimized to reduce trauma and heat dissipation, which can result in tissue damage for human applications and the system needs to be implantable and wireless. The practical solution for developing such systems is system-on-a-chip, based on ultra-low-power mixed-mode and wideband RFIC designs. They, however, impose a number of challenges that may require nontraditional solutions. In this paper, we present a fully differential low-power low-noise preamplifier suitable for recording biological signals, from a few mHz up to 10 kHz. This amplifier has a bandpass filter that is tunable between 10 mHz and 10 kHz, and has been designed and simulated in a standard 90-nm CMOS process. The circuit consumes 10 μW from a 1.2 V supply and provides a gain of 40 dB and an output swing of ±0.5 V with a total harmonic distortion of less than 0.5%. The total input-referred noise level is 4.6 μV integrating the noise over 0.01 Hz to 10 kHz.

scholarly journals Low-Power pH Sensor Based on Narrow Channel Open-Gated Al0.25Ga0.75N/GaN HEMT and Package Integrated Polydimethylsiloxane Microchannels

Materials ◽  
2020 ◽  
Vol 13 (22) ◽  
pp. 5282
Author(s):  
Xianghong Yang ◽  
Jiapei Ao ◽  
Sichen Wu ◽  
Shenhui Ma ◽  
Xin Li ◽  
...  
Keyword(s):  
Low Power ◽  
Ph Sensor ◽  
Reducing Power ◽  
High Electron Mobility Transistor ◽  
Narrow Channel ◽  
Harsh Environments ◽  
High Electron ◽  
Ultra Low Power ◽  
Excellent Stability

pH sensors with low-power and strong anti-interference are extremely important for industrial online real-time detection. Herein, a narrow channel pH sensor based on Al0.25Ga0.75N/GaN high electron mobility transistor (HEMT) with package integrated Polydimethylsiloxane (PDMS) microchannels is proposed. The fabricated device has shown potential advantages in improving stability and reducing power consumption in response to pH changes of the solution. The performance of the pH sensor was demonstrated where the preliminary results showed an ultra-low power (<5.0 μW) at VDS = 1.0 V. Meanwhile, the sensitivity was 0.06 μA/V·pH in the range of pH = 2 to pH = 10, and the resolution of the sensor was 0.1 pH. The improvement in performance of the proposed sensor can be related to the narrow channel and microchannel, which can be attributed to better surface GaxOy in a microchannel with larger H+ and HO− concentration on the sensing surface during the detection process. The low-power sensor with excellent stability can be widely used in various unattended or harsh environments, and it is more conducive to integration and intelligence, which lays the foundation for online monitoring in vivo.

Melatonin modifies tumor hypoxia and metabolism by inhibiting HIF-1α and energy metabolic pathway in the in vitro and in vivo models of breast cancer

2019 ◽  
Vol 2 (4) ◽  
pp. 83-98 ◽  
Author(s):  
André De Lima Mota ◽  
Bruna Vitorasso Jardim-Perassi ◽  
Tialfi Bergamin De Castro ◽  
Jucimara Colombo ◽  
Nathália Martins Sonehara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glucose Metabolism ◽  
Tumor Growth ◽  
Tumor Cells ◽  
Carbonic Anhydrases ◽  
In Vivo Models ◽  
Ca Ix ◽  
Gene And Protein Expression

Breast cancer is the most common cancer among women and has a high mortality rate. Adverse conditions in the tumor microenvironment, such as hypoxia and acidosis, may exert selective pressure on the tumor, selecting subpopulations of tumor cells with advantages for survival in this environment. In this context, therapeutic agents that can modify these conditions, and consequently the intratumoral heterogeneity need to be explored. Melatonin, in addition to its physiological effects, exhibits important anti-tumor actions which may associate with modification of hypoxia and Warburg effect. In this study, we have evaluated the action of melatonin on tumor growth and tumor metabolism by different markers of hypoxia and glucose metabolism (HIF-1α, glucose transporters GLUT1 and GLUT3 and carbonic anhydrases CA-IX and CA-XII) in triple negative breast cancer model. In an in vitro study, gene and protein expressions of these markers were evaluated by quantitative real-time PCR and immunocytochemistry, respectively. The effects of melatonin were also tested in a MDA-MB-231 xenograft animal model. Results showed that melatonin treatment reduced the viability of MDA-MB-231 cells and tumor growth in Balb/c nude mice (p <0.05). The treatment significantly decreased HIF-1α gene and protein expression concomitantly with the expression of GLUT1, GLUT3, CA-IX and CA-XII (p <0.05). These results strongly suggest that melatonin down-regulates HIF-1α expression and regulates glucose metabolism in breast tumor cells, therefore, controlling hypoxia and tumor progression. 

The truncated somatostatin receptor sst5TMD4 stimulates the production of pro-angiogenic factors in in vitro and in vivo breast cancer models

2014 ◽  
Author(s):  
Raul M Luque ◽  
Mario Duran-Prado ◽  
David Rincon-Fernandez ◽  
Marta Hergueta-Redondo ◽  
Michael D Culler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Somatostatin Receptor ◽  
Angiogenic Factors ◽  
Cancer Models

An Ultra-low Power Consumption MAC Protocol Complied with IEEE 802.15.4/4e for Wireless Smart Utility Networks

2016 ◽  
Vol 136 (11) ◽  
pp. 1555-1566 ◽  
Author(s):  
Jun Fujiwara ◽  
Hiroshi Harada ◽  
Takuya Kawata ◽  
Kentaro Sakamoto ◽  
Sota Tsuchiya ◽  
...  
Keyword(s):  
Power Consumption ◽  
Low Power ◽  
Ieee 802.15.4 ◽  
Mac Protocol ◽  
Low Power Consumption ◽  
Ultra Low Power
Sign in / Sign up

Export Citation Format

Share Document